258 related articles for article (PubMed ID: 11911607)
41. Gene expression profiling in drug discovery and development.
Stratowa C; Wilgenbus KK
Curr Opin Mol Ther; 1999 Dec; 1(6):671-9. PubMed ID: 19629863
[TBL] [Abstract][Full Text] [Related]
42. Patentees research and development expenditure in Canada.
Li S; Tomalin A
J Pharm Pharm Sci; 2002; 5(1):5-11. PubMed ID: 12042113
[TBL] [Abstract][Full Text] [Related]
43. Novel technology to improve pharmaceutical productivity.
Krebs R
Curr Opin Drug Discov Devel; 1999 May; 2(3):239-43. PubMed ID: 19649952
[TBL] [Abstract][Full Text] [Related]
44. Helping science to succeed: improving processes in R&D.
Sewing A; Winchester T; Carnell P; Hampton D; Keighley W
Drug Discov Today; 2008 Mar; 13(5-6):227-33. PubMed ID: 18342798
[TBL] [Abstract][Full Text] [Related]
45. Molecular properties that influence oral drug-like behavior.
Lajiness MS; Vieth M; Erickson J
Curr Opin Drug Discov Devel; 2004 Jul; 7(4):470-7. PubMed ID: 15338956
[TBL] [Abstract][Full Text] [Related]
46. Are we approaching the post-blockbuster era? Pharmacodiagnostics and rational drug development.
Jørgensen JT
Expert Rev Mol Diagn; 2008 Nov; 8(6):689-95. PubMed ID: 18999921
[TBL] [Abstract][Full Text] [Related]
47. Handing over the baton: connecting medicinal chemistry with process R&D.
Federsel HJ
Drug News Perspect; 2008 May; 21(4):193-9. PubMed ID: 18560618
[TBL] [Abstract][Full Text] [Related]
48. Procedures and methods of benefit assessments for medicines in Germany.
Bekkering GE; Kleijnen J
Eur J Health Econ; 2008 Nov; 9 Suppl 1():5-29. PubMed ID: 18987905
[TBL] [Abstract][Full Text] [Related]
49. Enabling high-throughput discovery.
Vaschetto M; Weissbrod T; Bodle D; Güner O
Curr Opin Drug Discov Devel; 2003 May; 6(3):377-83. PubMed ID: 12833671
[TBL] [Abstract][Full Text] [Related]
50. Drug costs: research and development costs: the great illusion.
Prescrire Int; 2004 Feb; 13(69):32-6. PubMed ID: 15055226
[TBL] [Abstract][Full Text] [Related]
51. Reducing medication errors and increasing patient safety: case studies in clinical pharmacology.
Benjamin DM
J Clin Pharmacol; 2003 Jul; 43(7):768-83. PubMed ID: 12856392
[TBL] [Abstract][Full Text] [Related]
52. Trends in antimicrobial drug development: implications for the future.
Spellberg B; Powers JH; Brass EP; Miller LG; Edwards JE
Clin Infect Dis; 2004 May; 38(9):1279-86. PubMed ID: 15127341
[TBL] [Abstract][Full Text] [Related]
53. Rebuilding the R&D engine in big pharma.
Garnier JP
Harv Bus Rev; 2008 May; 86(5):68-70, 72-6, 128. PubMed ID: 18543809
[TBL] [Abstract][Full Text] [Related]
54. Compound scale-up at the discovery-development interface.
Nikitenko AA
Curr Opin Drug Discov Devel; 2006 Nov; 9(6):729-40. PubMed ID: 17117683
[TBL] [Abstract][Full Text] [Related]
55. Information technology and supply chain management: a study of the food industry.
Hill CA
Hosp Mater Manage Q; 2000 Aug; 22(1):53-8. PubMed ID: 11183387
[TBL] [Abstract][Full Text] [Related]
56. Eliminate (don't automate) inventory tracking.
Stahl RA
Hosp Mater Manage Q; 1997 Aug; 19(1):43-9. PubMed ID: 10168472
[TBL] [Abstract][Full Text] [Related]
57. Biotechnology's metamorphosis into a drug discovery industry.
Drews J
Nat Biotechnol; 1998 May; 16 Suppl():22-4. PubMed ID: 9591258
[No Abstract] [Full Text] [Related]
58. Discovery of innovative therapeutics: today's realities and tomorrow's vision. 1. Criticisms faced by the pharmaceutical industry.
Abou-Gharbia M; Childers WE
J Med Chem; 2013 Jul; 56(14):5659-72. PubMed ID: 23557017
[TBL] [Abstract][Full Text] [Related]
59. Research and development productivity map: visualization of industry status.
Shimura H; Masuda S; Kimura H
J Clin Pharm Ther; 2014 Apr; 39(2):175-80. PubMed ID: 24438433
[TBL] [Abstract][Full Text] [Related]
60. Chemical synthesis in microreactors.
Watts P; Haswell SJ
Methods Mol Biol; 2010; 583():109-20. PubMed ID: 19763461
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
